2016
DOI: 10.1055/s-0036-1581141
|View full text |Cite
|
Sign up to set email alerts
|

Evidence-Based Management of Vascular Malformations

Abstract: Vascular malformations of the head and neck are complex lesions that are notoriously difficult to manage. Treatment of these lesions often requires a multispecialty and multimodal approach. In the modern era of evidence-based medicine, it has become imperative for clinicians to incorporate evidence-based treatment algorithms into their everyday practices. With general widespread inundation of the literature with levels IV and V clinical evidence, however, it is often difficult to draw meaningful conclusions th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
27
0
8

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 30 publications
(35 citation statements)
references
References 122 publications
(211 reference statements)
0
27
0
8
Order By: Relevance
“…The mTOR pathway is involved in various pathological mechanisms of lymphangiogenesis, lymphatic metastasis and several cancer developments, including colorectal cancer, gastric cancer, liver cancer, breast cancer and uterine cancer 15–17 . Sirolimus known as a mTOR inhibitor has an antiproliferative effect on lymphatic vessels, and is clinically used for a difficult‐to‐treat lymphatic anomalies 12,13,18–20 . Sirolimus binds the FK‐binding protein 12, resulting in a complex that prevents phosphorylation and activation of 4EBP1 and S6K1 21,22 .…”
Section: Discussionmentioning
confidence: 99%
“…The mTOR pathway is involved in various pathological mechanisms of lymphangiogenesis, lymphatic metastasis and several cancer developments, including colorectal cancer, gastric cancer, liver cancer, breast cancer and uterine cancer 15–17 . Sirolimus known as a mTOR inhibitor has an antiproliferative effect on lymphatic vessels, and is clinically used for a difficult‐to‐treat lymphatic anomalies 12,13,18–20 . Sirolimus binds the FK‐binding protein 12, resulting in a complex that prevents phosphorylation and activation of 4EBP1 and S6K1 21,22 .…”
Section: Discussionmentioning
confidence: 99%
“…Embolization or surgery, as a unique treatment or in combination, has been shown to be potentially curative. 10,12 However, surgery is not always feasible due to the diffuse and deep extension of some malformations and their extensive collateral recruitment, such as in our patient. Unfortunately, malformations of this complexity are mostly incurable with either embolization alone or post-embolization excision.…”
Section: Discussionmentioning
confidence: 76%
“…12 Under such circumstances, subsequent mechanical obliteration is not likely and the role of antiangiogenic drugs will need to be further explored. In addition to bevacizumab and bleomycin, there is a renewed interest in the use of thalidomide as a therapeutic agent for these lesions.…”
Section: Discussionmentioning
confidence: 99%
“…AVM's and BCC's manifests with clinical overlap but can be distinguished by dermoscopy and histological assessment. An early accurate diagnosis of AVM's is important since patients receiving surgical intervention sooner will have a better outcome 5, 14…”
Section: Discussionmentioning
confidence: 99%